Summary
Boston Scientific Corporation (BSX) filed an 8-K report on November 6, 2019, detailing significant financing activities. The company announced the early results and pricing of a cash tender offer for up to $1.0 billion of its outstanding senior notes across several maturity dates. This initiative is aimed at managing its existing debt structure.
Key Highlights
- 1Announced early results and pricing for a cash tender offer to repurchase up to $1.0 billion of outstanding senior notes.
- 2The tender offer covers notes due in 2023, 2028, 2025, and 2022.
- 3Priced a public offering of €900,000,000 (approximately $1.0 billion) in 0.625% notes due 2027.
- 4The offering is expected to close on November 12, 2019.
- 5Proceeds from the new note offering are intended to fund the tender offer.
- 6Any remaining proceeds from the offering will be used for repayment of other indebtedness and general corporate purposes.
- 7The tender offer's consummation is subject to a financing condition.